Harmony Biosciences Holdings, INC

Harmony Biosciences announced record Q2 2026 revenue of $261.3 million, a 30% year-over-year increase, and presented encouraging clinical data for its orexin-2 agonist BP-205.

Harmony Biosciences announced preliminary record net product revenue of approximately $261 million for Q2 2026, a 30% year-over-year increase, and reaffirmed its full-year revenue guidance.

Harmony Biosciences announced Q1 2026 financial results, with WAKIX net revenue growing 17% year-over-year to $215.4 million, and reaffirmed its full-year 2026 net revenue guidance of over $1 billion.

Harmony Biosciences Holdings, Inc. announced the appointment of Glenn Reicin as its new Chief Financial Officer, effective April 14, 2026, and reiterated its 2026 net revenue guidance of over $1 billion for Wakix sales.

Harmony Biosciences has appointed Peter Anastasiou as Chief Operating Officer and announced strategic changes to its Board of Directors.

Harmony Biosciences announced robust 2025 financial results, with WAKIX net revenue reaching $868.5 million, and reiterated its 2026 guidance of over $1 billion, driven by pipeline advancements and market expansion.

Harmony Biosciences announced robust Q2 2026 results, driven by significant net product revenue growth, strategic pipeline advancements, and effective cost management.

Harmony Biosciences reported a 16.6% increase in net product revenue for Q1 2026, driven by unit shipments and a price increase, while research and development expenses more than doubled due to significant upfront license fees.

Harmony Biosciences reported strong financial growth in Q3 2025, driven by WAKIX sales, while advancing its diverse neurological pipeline despite a Phase 3 setback for ZYN002.

Harmony Biosciences Holdings, Inc. reported significant revenue and net income growth for the second quarter and first half of 2025, driven by strong WAKIX sales and progress across its expanded neuroscience pipeline.

Harmony Biosciences Holdings, Inc. announces a 19.5% increase in net product revenue for Q1 2025, driven by increased WAKIX sales and a price increase.

Harmony Biosciences reported a 16.1% increase in net product revenue for the third quarter of 2024, alongside significant advancements in their clinical pipeline.

Harmony Biosciences reports strong 2025 revenue growth for WAKIX, expands its neuroscience pipeline, and navigates generic competition.

Harmony Biosciences Holdings, Inc. announces its 2024 financial results, highlighting growth in WAKIX sales while addressing regulatory challenges and pipeline expansion.

Harmony Biosciences has filed an amendment to its annual report to include details of Rule 10b5-1 trading arrangements by its officers.

Harmony Biosciences Holdings, Inc. released its 2023 annual report, highlighting financial performance and progress in its clinical development programs.

Director Geno J. Germano was granted 21,231 stock options in Harmony Biosciences Holdings, Inc. as part of standard compensation.

Harmony Biosciences Holdings, Inc. reports that Director Linda M. Szyper acquired stock options on May 14, 2026, as detailed in a Form 4 filing.

Harmony Biosciences Holdings, Inc. reports that Director Philip Ron M acquired stock options on May 14, 2026.

Harmony Biosciences Holdings, Inc. Director Mark Graf acquired stock options, as disclosed in a Form 4 filing.

Harmony Biosciences Holdings, Inc. Director Juan A. Sabater acquired 21,872 stock options with an exercise price of $30.76, vesting under specific service conditions.

Harmony Biosciences Holdings, Inc. reports a Form 4 filing detailing changes in beneficial ownership for Chief Medical Officer Kumar Budur, including stock withholding and RSUs.

Harmony Biosciences Holdings, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on May 14, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.

Harmony Biosciences Holdings, Inc. has filed a definitive proxy statement with the SEC.

Harmony Biosciences will hold its annual meeting of stockholders virtually on May 15, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Harmony Biosciences Holdings, Inc. has filed a definitive proxy statement with the SEC.

Harmony Biosciences Holdings will hold its 2024 annual meeting of stockholders virtually on May 29, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Vanguard Portfolio Management has reported beneficial ownership of over 5% of Harmony Biosciences Holdings Inc. common stock as of June 30, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Harmony Biosciences Holdings Inc. following an internal corporate realignment.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have jointly disclosed a beneficial ownership of 5.4% in Harmony Biosciences Holdings Inc. common stock as of December 31, 2025.

Valor Equity Partners and affiliated entities, including Antonio J. Gracias and Juan A. Sabater, have filed an amended Schedule 13G indicating their beneficial ownership in Harmony Biosciences Holdings, Inc. is now below 5% for all reporting persons.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 6.7% beneficial ownership stake in Harmony Biosciences Holdings Inc. as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 10.1% beneficial ownership stake in Harmony Biosciences Holdings, Inc. as of March 31, 2025.